RhumbLine Advisers’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $297K | Buy |
77,494
+2,018
| +3% | +$7.73K | ﹤0.01% | 2991 |
|
|
2025
Q1 | $434K | Sell |
75,476
-2,712
| -3% | -$15.6K | ﹤0.01% | 2661 |
|
|
2024
Q4 | $390K | Buy |
78,188
+1,087
| +1% | +$5.42K | ﹤0.01% | 2825 |
|
|
2024
Q3 | $416K | Buy |
77,101
+120
| +0.2% | +$647 | ﹤0.01% | 2831 |
|
|
2024
Q2 | $255K | Buy |
76,981
+12,907
| +20% | +$42.7K | ﹤0.01% | 3089 |
|
|
2024
Q1 | $210K | Buy |
64,074
+2,211
| +4% | +$7.23K | ﹤0.01% | 3153 |
|
|
2023
Q4 | $217K | Sell |
61,863
-649
| -1% | -$2.28K | ﹤0.01% | 3147 |
|
|
2023
Q3 | $418K | Buy |
62,512
+3,018
| +5% | +$20.2K | ﹤0.01% | 2718 |
|
|
2023
Q2 | $499K | Buy |
+59,494
| New | +$499K | ﹤0.01% | 2685 |
|
|
2022
Q2 | – | Sell |
-47,596
| Closed | -$212K | – | 3092 |
|
|
2022
Q1 | $212K | Buy |
47,596
+4,996
| +12% | +$22.3K | ﹤0.01% | 2741 |
|
|
2021
Q4 | $170K | Sell |
42,600
-853
| -2% | -$3.4K | ﹤0.01% | 2868 |
|
|
2021
Q3 | $382K | Buy |
43,453
+1,923
| +5% | +$16.9K | ﹤0.01% | 2672 |
|
|
2021
Q2 | $471K | Buy |
+41,530
| New | +$471K | ﹤0.01% | 2589 |
|
|
2020
Q2 | – | Sell |
-30,784
| Closed | -$76K | – | 3061 |
|
|
2020
Q1 | $76K | Hold |
30,784
| – | – | ﹤0.01% | 2823 |
|
|
2019
Q4 | $179K | Buy |
30,784
+143
| +0.5% | +$832 | ﹤0.01% | 2779 |
|
|
2019
Q3 | $161K | Buy |
30,641
+706
| +2% | +$3.71K | ﹤0.01% | 2799 |
|
|
2019
Q2 | $180K | Buy |
29,935
+2,752
| +10% | +$16.5K | ﹤0.01% | 2817 |
|
|
2019
Q1 | $245K | Buy |
27,183
+4,010
| +17% | +$36.1K | ﹤0.01% | 2652 |
|
|
2018
Q4 | $192K | Buy |
23,173
+9,260
| +67% | +$76.7K | ﹤0.01% | 2748 |
|
|
2018
Q3 | $192K | Sell |
13,913
-343
| -2% | -$4.73K | ﹤0.01% | 2738 |
|
|
2018
Q2 | $113K | Buy |
+14,256
| New | +$113K | ﹤0.01% | 2859 |
|